Aarti Pharmalabs Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹418Cr
- −8.7% YoY
- +8.3% QoQ
- Net profit
- ₹28Cr
- −49.1% YoY
- −44% QoQ
- Margin
- 18%
- −2 pp YoY
- −6 pp QoQ
Guidance rank: #5 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).
From Aarti Pharmalabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth.
- New molecules moving from development to commercial phase will drive sales, with larger growth anticipated in FY '27 and beyond.
- API business to normalize and ramp up in H2 FY '26 after inventory corrections and product mix optimization, including oncology and steroid APIs, with major launches in FY '27 and FY '28.
- Atali plant will become fully operational in 2-3 quarters, boosting Intermediate and CDMO business revenue from FY '27 onward.
- Xanthine capacity expansion to 9,000 tons/year by end of FY '26, with gradual ramp-up over 2-3 years expected to capture ~25% market share.
2 more points from Aarti Pharmalabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
- Xanthine expansion: Capacity increased from 5,000 to 9,000 metric tons (annual installed capacity) by end of FY '26; expansion is brownfield with phased operationalization.
- Facility upgrades: Focus on debottlenecking and standardizing production, including at Ganesh Polychem to improve cost efficiency and profitability.
- Site shifting plan: Future plan to shift Dombivli site within the year as part of strategic operational improvements.
2 more points from Aarti Pharmalabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The CDMO-CMO segment currently has 59 active projects, with 39 in the commercial stage and 20 under various stages of development at the customer's end.
- The company is working with 21 customers in this segment and is on track to achieve and exceed the earlier estimated sales target of 30% to 40% Y-o-Y growth.
- Management is actively participating in several RFPs (Requests for Proposals) to increase the CDMO project funnel, including expanding geographical presence in Europe and North America to boost business development.
2 more points from Aarti Pharmalabs Ltd's call on order book
Create a free account to keep reading this call
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Aarti Pharmalabs Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 418 | 458 | -8.7% | 386 | +8.3% |
| Operating profit (EBITDA) | 74 | 94 | -21.3% | 93 | -20.4% |
| Operating margin | 18% | 20% | -2 pp | 24% | -6 pp |
| Profit before tax | 39 | 72 | -45.8% | 65 | -40% |
| Net profit (PAT) | 28 | 55 | -49.1% | 50 | -44% |
| EPS (₹) | 3.08 | 6.03 | -48.9% | 5.46 | -43.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q2 FY26 results?
CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
